A two-faced selectivity solution to target SMARCA2 for cancer therapy
Open Access
- 31 January 2023
- journal article
- editorial
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-3
Abstract
Two new studies exploring PROTAC-mediated degradation of SMARCA2 for cancer therapy solve an apparently intractable selectivity challenge with SMARCA4 by utilising the requirement for a productive ternary complex between the protein, PROTAC and ligase complex.Keywords
This publication has 15 references indexed in Scilit:
- The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung CancerClinical Cancer Research, 2020
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designNature Chemical Biology, 2019
- Chromatin regulatory mechanisms and therapeutic opportunities in cancerNature Cell Biology, 2019
- Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling ComplexesCell, 2018
- Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant CancersJournal of Medicinal Chemistry, 2018
- Lessons in PROTAC Design from Selective Degradation with a Promiscuous WarheadCell Chemical Biology, 2018
- A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase DegraderCell Chemical Biology, 2018
- The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesCancer Research, 2015
- Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical CandidatesChemistry & Biology, 2014
- Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradationProceedings of the National Academy of Sciences of the United States of America, 2001